Mycobacterium africanum presenting as a brain mass

Infectious Diseases in Clinical Practice

Volumn 16, Issue 5, 2008, Pages 327-329

  Bhanot, Nitin ^a   Badem, Olga ^a   Mathew, Liby ^a   Haran, Mehandi ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANAMNESIS; ARTICLE; BRAIN BIOPSY; BRAIN DAMAGE; CASE REPORT; CLINICAL FEATURE; FEMALE; GRANULOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MYCOBACTERIUM AFRICANUM; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE;

EID: 67649989768     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e3181637a0f     Document Type: Article

References (17)

1. Castets M, Boisvert H, Grumbach F, et al. Tuberculosis bacilli of the African type: preliminary note. Rev Tuberc Pneumol (Paris). 1968; 32:179-184.
2. Baril L, Caumes E, Truffot-Pernot C, et al. Tuberculosis caused by Mycobacterium africanum associated with involvement of the upper and lower respiratory tract, skin, and mucosa. Clin Infect Dis. 1995;21: 653-655.
3. Grange JM, Yates MD. Incidence and nature of human tuberculosis due to Mycobacterium africanum in South-East England: 1977-87. Epidemiol Infect. 1989;103:127-132.
4. Desmond E, Ahmed AT, Probert WS, et al. Mycobacterium africanum cases, California. Emerg Infect Dis. 2004;10:921-923.
5. Pfyffer GE, Brown-Elliott BA, Wallace RJ Jr. Mycobacterium: general characteristics, isolation, and staining procedures. In: Murray PR, ed. Manual of Clinical Microbiology. 8th ed. Washington DC: ASM press; 2003:535.
6. Mostowy S, Onipede A, Gagneux S, et al. Genomic analysis distinguishes Mycobacterium africanum. J Clin Microbiol. 2004;42: 3594-3599.
7. Frothingham R, Strickland PL, Bretzel G, et al. Phenotypic and genotypic characterization of Mycobacterium africanum isolates from West Africa. J Clin Microbiol. 1999;37:1921-1926.
8. Viana-Niero C, Gutierrez C, Sola C, et al. Genetic diversity of Mycobacterium africanum clinical isolates based on IS6110-restriction fragment length polymorphism analysis, spoligotyping, and variable number of tandem DNA repeats. J Clin Microbiol. 2001;39:57-65.
9. Johnson JL, Ellner JJ. Tuberculosis and atypical mycobacterial infections. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases - Principles, Pathogens, & Practice. 2nd ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2006:394.
10. de Jong BC, Hill PC, Aiken A, et al. Clinical presentation and outcome of tuberculosis patients infected by M. africanum versus M. tuberculosis. Int J Tuberc Lung Dis. 2007;11:450-456.
11. Awada A, Daif AK, Pirani M, et al. Evolution of brain tuberculomas under standard antituberculous treatment. J Neurol Sci. 1998;156:47-52.
12. Choudhury AR. Non-surgical treatment of tuberculomas of the brain. Br J Neurosurg. 1989;3:643-653.
13. Domingo Z, Peter JC. Intracranial tuberculomas. An assessment of a therapeutic 4-drug trial in 35 children. Pediatr Neurosci. 1989; 15:161-166.
14. Kumar R, Prakash M, Jha S. Paradoxical response to chemotherapy in neurotuberculosis. Pediatr Neurosurg. 2006;42:214-222.
15. Gupta M, Bajaj BK, Khwaja G. Paradoxical response in patients with CNS tuberculosis. J Assoc Physicians India. 2003;51: 257-260.
16. Afghani B, Lieberman JM. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis. 1994;19:1092-1099.
17. Bas NS, Guzey FK, Emel E, et al. Paradoxical intracranial tuberculoma requiring surgical treatment. Pediatr Neurosurg. 2005;41:201-205.